162 related articles for article (PubMed ID: 38170137)
21. Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature.
Briganti SI; Naciu AM; Tabacco G; Cesareo R; Napoli N; Trimboli P; Castellana M; Manfrini S; Palermo A
Int J Endocrinol; 2021; 2021():8902367. PubMed ID: 33510787
[TBL] [Abstract][Full Text] [Related]
22. Community-dwelling older adults' awareness of the inappropriate use of proton pump inhibitors.
Rababa M; Rababa'h A
BMC Geriatr; 2020 Oct; 20(1):431. PubMed ID: 33121444
[TBL] [Abstract][Full Text] [Related]
23. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
Fournier MR; Targownik LE; Leslie WD
Maturitas; 2009 Sep; 64(1):9-13. PubMed ID: 19674854
[TBL] [Abstract][Full Text] [Related]
24. The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density.
Fattahi MR; Niknam R; Shams M; Anushiravani A; Taghavi SA; Omrani GR; Mahmoudi L
Risk Manag Healthc Policy; 2019; 12():349-355. PubMed ID: 31853206
[TBL] [Abstract][Full Text] [Related]
25. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
Lewis JR; Barre D; Zhu K; Ivey KL; Lim EM; Hughes J; Prince RL
J Bone Miner Res; 2014 Nov; 29(11):2489-97. PubMed ID: 24825180
[TBL] [Abstract][Full Text] [Related]
26. Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
Abrahamsen B; Vestergaard P
Bone; 2013 Nov; 57(1):269-71. PubMed ID: 23973557
[TBL] [Abstract][Full Text] [Related]
27. Proton pump inhibitors and risk of bone fractures.
Leontiadis GI; Moayyedi P
Curr Treat Options Gastroenterol; 2014 Dec; 12(4):414-23. PubMed ID: 25209137
[TBL] [Abstract][Full Text] [Related]
28. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
Targownik LE; Leslie WD; Davison KS; Goltzman D; Jamal SA; Kreiger N; Josse RG; Kaiser SM; Kovacs CS; Prior JC; Zhou W;
Am J Gastroenterol; 2012 Sep; 107(9):1361-9. PubMed ID: 22777336
[TBL] [Abstract][Full Text] [Related]
29. Increased Risk of Fractures and Use of Proton Pump Inhibitors in Menopausal Women: A Systematic Review and Meta-Analysis.
da Maia TF; de Camargo BG; Pereira ME; de Oliveira CS; Guiloski IC
Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36294082
[TBL] [Abstract][Full Text] [Related]
30. Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Bone Rep; 2019 Jun; 10():100204. PubMed ID: 30993153
[TBL] [Abstract][Full Text] [Related]
31. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved.
Thong BKS; Ima-Nirwana S; Chin KY
Int J Environ Res Public Health; 2019 May; 16(9):. PubMed ID: 31060319
[TBL] [Abstract][Full Text] [Related]
32. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
33. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
[TBL] [Abstract][Full Text] [Related]
34. Proton pump inhibitors and fracture risk: true effect or residual confounding?
Bodmer M; Meier C; Kraenzlin ME; Meier CR
Drug Saf; 2010 Oct; 33(10):843-52. PubMed ID: 20812769
[TBL] [Abstract][Full Text] [Related]
35. Considerations for the use of proton-pump inhibitors in older adults.
Desilets AR; Asal NJ; Dunican KC
Consult Pharm; 2012 Feb; 27(2):114-20. PubMed ID: 22330952
[TBL] [Abstract][Full Text] [Related]
36. The effect of proton pump-inhibiting drugs on mineral metabolism.
Insogna KL
Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S2-4. PubMed ID: 19262542
[TBL] [Abstract][Full Text] [Related]
37. Effect of long-term proton pump inhibitors on bone mineral density.
Romdhane H; Ayadi S; Elleuch N; Abdelghani K
Tunis Med; 2018 Mar; 96(3):193-197. PubMed ID: 30325487
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure.
Targownik LE; Goertzen AL; Luo Y; Leslie WD
Am J Gastroenterol; 2017 Jan; 112(1):95-101. PubMed ID: 27845341
[TBL] [Abstract][Full Text] [Related]
39. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
40. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
